title: It is possible that tumour-infiltrating granulocytes promote tumour progression.
abstract: Several lines of evidence indicate that tumour-infiltrating granulocytes (TIGs) promote tumour growth and progression. However, the prognostic significance of TIGs, the relationship between TIGs and Fas ligand (FasL) expressed on tumour cells remains unclear and warrants investigation. Using immunnostaining, we retrospectively investigated TIGs and FasL in 130 tissue specimens from gastric carcinoma. We analyzed the correlation among these markers, their association with clinicopathologic features and prognosis. The number of TIGs was significantly associated with FasL-expression (P=0.002). Further, TIGs were significantly associated with depth of tumour invasion, lymph node metastasis and tumour stage. Calculating the prognostic relevance, in multivariate analysis, TIGs [relative risk (RR)=1.014; 95% CI=1.002-1.027; P=0.015] and tumour stage were statistically significant factors for survival. Our results suggest that TIGs are conveniently measured by the immunostaining method, and possibly serve as an independent factor of prognosis in patients with gastric carcinoma. This is based on the fact that TIGs were significantly associated with tumour stage and shorter survival time.
authors.affiliation: Fourth Department of Surgery, Kasumigaura Hospital Tokyo Medical University, Inashiki-Gun, Ibaragi, Japan. lhrlhr9050@yahoo.com
authors.forename: Huanran
authors.initials: H
authors.lastname: Liu
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ubukata
authors.forename: Takanobu
authors.initials: T
authors.lastname: Tabuchi
authors.forename: Akira
authors.initials: A
authors.lastname: Takemura
authors.forename: Gyou
authors.initials: G
authors.lastname: Motohashi
authors.forename: Motoi
authors.initials: M
authors.lastname: Nishimura
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Satani
authors.forename: Jianwei
authors.initials: J
authors.lastname: Hong
authors.forename: Motonobu
authors.initials: M
authors.lastname: Katano
authors.forename: Ichiro
authors.initials: I
authors.lastname: Nakada
authors.forename: Abbi R
authors.initials: AR
authors.lastname: Saniabadi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Tabuchi
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000556:secondary / Q000601:surgery; D000368:Aged; D018450:Disease Progression; D053222:Fas Ligand Protein / Q000032:analysis; D005260:Female; D005743:Gastrectomy; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein